Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.

Nature communications - 19 May 2026

Chithelen Janice, Lovett David H, Wang Kevin, Torres Yanagisawa Akari E, Caccin Farah N M, Iketani Sho

Abstract excerpt

SARS-CoV-2 is now endemic, with infections commonplace. While much of the population now has immunity, some subsets remain at risk. For such individuals, small-molecule antivirals are the frontline treatment. However, studies have identified resistance-conferring mutations to these compounds, and there are now cases of resistant viruses emerging during treatment. These occurrences make clear the need to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Azabicyclo Compounds
Share to Coronavirus 3C Proteases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to Drug Resistance, Viral

Share to Protease Inhibitors

Share to Pyrrolidinones

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 42156379
DOI: 10.1038/s41467-026-73444-y
PMCID: PMC13381909

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.PMID 42156379Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirSemantic proximity Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.Semantic proximity Read ↗

Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main proteaseSemantic proximity Read ↗

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierSemantic proximity Read ↗

SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.Semantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor <i>in vitro</i> and confer resistance to nirmatrelvirSemantic proximity Read ↗

Rapid resistance profiling of SARS-CoV-2 protease inhibitorsSemantic proximity Read ↗

Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals.Semantic proximity Read ↗

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read ↗

SARS-CoV-2 resistance pathways to EDP-235.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.